Affymax (AFFY) 0.1610 $AFFY
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing - AFFY
Business Wire - Fri Sep 12, 12:31PM CDT
--EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF AFFYMAX, AND THEIR FAMILIES AND AFFILIATES.
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Affymax Reports Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:05PM CDT
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share) for the second quarter of 2013.
Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:20PM CDT
GlaxoSmithKline (GSK) and partner Genmab announced disappointing top-line data on their oncology drug, Arzerra.
Affymax Shares are Trading near Liquidation Value; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:00PM CDT
According to the National Kidney Foundation, chronic kidney disease affects over 26 million adults in the U.S., and is caused by diabetes and high blood pressure. As kidney functions deteriorate, the kidney's ability to produce red blood cells declines, and results in anemia. Anemia is a condition in which the patient's blood is deficient in red blood cells and hemoglobin. Kidney dialysis is expensive, and the cost of anemia drugs has been Medicare's single largest drug expenditure, amounting to $3.9 billion in 2007.
AstraZeneca's Olaparib Fails to Impress FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 10:10AM CDT
AstraZeneca (AZN) announced that the FDA's Oncologic Drugs Advisory Committee voted against accelerated approval of olaparib.
Affymax Board Announces Decision to Dissolve the Company
Business Wire - Tue Jun 24, 3:30PM CDT
Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders as soon as legally permitted and reasonably practicable after paying or making reasonable provision for all known and potential liabilities and other obligations of the Company. Based on the information the Company currently has available, which is subject to change, the Company estimates that the aggregate amount of the distribution to stockholders could be a few cents per share, based on 37,490,095 shares of common stock outstanding as of April 30, 2014 and the remaining cash of approximately $4 million as of May 2014.
OTC Daily Trading Focus List: Axxess Pharma, Inc. Petvivo Holdings, Inc. Integrated Cannabis Solutions, Inc. BreedIT Corp, Affymax, Inc.
PR Newswire Europe - Wed Jun 18, 10:46AM CDT
LONDON, June 18, 2014 /PRNewswire/ --
Affymax terminates Omontys' product collaboration and license agreement with Takeda
M2 - Mon Jun 16, 3:34AM CDT
Biopharmaceutical company Affymax (Other OTC:AFFY) revealed on Friday the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company of Osaka, Japan effective 10 September 2014.
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement
Business Wire - Fri Jun 13, 3:15PM CDT
Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys(R) (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014.
B&W Subsidiary Awarded Up to $302 Million in Contracts for Naval Reactors Fuel, Materials Services
Business Wire - Thu Feb 27, 7:00AM CST
The Babcock & Wilcox Company (B&W) (NYSE:BWC) announced today that its subsidiary Nuclear Fuel Services, Inc. (NFS) has been awarded two new contracts for fuel and materials services totaling up to approximately $302 million from the U.S. Department of Energy, Naval Reactors Laboratory Field Office.
OTC Daily Alert Stock Watch - Affymax, Inc. (OTCQB: AFFY)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Research and Markets: Residential Construction in Romania to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/hr4v2h/residential) has announced the addition of the "Residential Construction in Romania to 2017: Market Forecast" report to their offering.
Update on Ligand/Glaxo's Promacta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 5:00PM CST
Ligand announced that the FDA granted breakthrough therapy designation to Promacta.
Allergan Beats on Earnings by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 10:23AM CST
Allergan reported fourth quarter 2013 earnings of $1.35 per share.
Herb C. Cross to Join KaloBios as Chief Financial Officer
PR Newswire - Thu Sep 19, 3:05PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The company expects this transition will be completed in the October-November time frame. Mr. Cross was previously Chief Financial Officer of Affymax (Nasdaq: AFFY), a publicly traded biopharmaceutical company. KaloBios previously announced Mr. Cooper's decision to retire in order to dedicate more time to family and personal interests.
Traders Get Bullish on Shares of Affymax, Shares Up 11.6% (AFFY)
Comtex SmarTrend(R) - Thu Aug 29, 11:44AM CDT
Affymax (NASDAQ:AFFY) is one of today's best performing low-priced stocks, up 11.6% to $1.75 on 1.5x average daily volume. Affymax has traded 1.9 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (11.5% to the Dow's 0.4%) and outperformed the S&P 500 (11.5% to the S&P's 0.5%) during today's trading.
GSAT, AFFY, AAMRQ and NVIV added to OTC Active Stock Watch List at EPR
ACCESSWIRE - Tue Aug 27, 7:57AM CDT
New York, NY - (ACCESSWIRE) - 08/27/2013 - Equity Profile Report initiates its OTC Active Stock Watch List adding Globalstar Inc. (OTC:GSAT), Affymax, Inc. (OTC:AFFY), AMR Corporation (OTC:AAMRQ) and InVivo Therapeutics Holdings Corp. (OTC:NVIV)
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing - AFFY
Business Wire - Fri Sep 12, 12:31PM CDT
--EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF AFFYMAX, AND THEIR FAMILIES AND AFFILIATES.
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Affymax Reports Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:05PM CDT
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share) for the second quarter of 2013.
Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:20PM CDT
GlaxoSmithKline (GSK) and partner Genmab announced disappointing top-line data on their oncology drug, Arzerra.
Affymax Shares are Trading near Liquidation Value; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:00PM CDT
According to the National Kidney Foundation, chronic kidney disease affects over 26 million adults in the U.S., and is caused by diabetes and high blood pressure. As kidney functions deteriorate, the kidney's ability to produce red blood cells declines, and results in anemia. Anemia is a condition in which the patient's blood is deficient in red blood cells and hemoglobin. Kidney dialysis is expensive, and the cost of anemia drugs has been Medicare's single largest drug expenditure, amounting to $3.9 billion in 2007.
AstraZeneca's Olaparib Fails to Impress FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 10:10AM CDT
AstraZeneca (AZN) announced that the FDA's Oncologic Drugs Advisory Committee voted against accelerated approval of olaparib.
Affymax Board Announces Decision to Dissolve the Company
Business Wire - Tue Jun 24, 3:30PM CDT
Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders as soon as legally permitted and reasonably practicable after paying or making reasonable provision for all known and potential liabilities and other obligations of the Company. Based on the information the Company currently has available, which is subject to change, the Company estimates that the aggregate amount of the distribution to stockholders could be a few cents per share, based on 37,490,095 shares of common stock outstanding as of April 30, 2014 and the remaining cash of approximately $4 million as of May 2014.
OTC Daily Trading Focus List: Axxess Pharma, Inc. Petvivo Holdings, Inc. Integrated Cannabis Solutions, Inc. BreedIT Corp, Affymax, Inc.
PR Newswire Europe - Wed Jun 18, 10:46AM CDT
LONDON, June 18, 2014 /PRNewswire/ --
Affymax terminates Omontys' product collaboration and license agreement with Takeda
M2 - Mon Jun 16, 3:34AM CDT
Biopharmaceutical company Affymax (Other OTC:AFFY) revealed on Friday the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company of Osaka, Japan effective 10 September 2014.
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement
Business Wire - Fri Jun 13, 3:15PM CDT
Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys(R) (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014.
B&W Subsidiary Awarded Up to $302 Million in Contracts for Naval Reactors Fuel, Materials Services
Business Wire - Thu Feb 27, 7:00AM CST
The Babcock & Wilcox Company (B&W) (NYSE:BWC) announced today that its subsidiary Nuclear Fuel Services, Inc. (NFS) has been awarded two new contracts for fuel and materials services totaling up to approximately $302 million from the U.S. Department of Energy, Naval Reactors Laboratory Field Office.
OTC Daily Alert Stock Watch - Affymax, Inc. (OTCQB: AFFY)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Research and Markets: Residential Construction in Romania to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/hr4v2h/residential) has announced the addition of the "Residential Construction in Romania to 2017: Market Forecast" report to their offering.
Update on Ligand/Glaxo's Promacta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 5:00PM CST
Ligand announced that the FDA granted breakthrough therapy designation to Promacta.
Allergan Beats on Earnings by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 10:23AM CST
Allergan reported fourth quarter 2013 earnings of $1.35 per share.
Herb C. Cross to Join KaloBios as Chief Financial Officer
PR Newswire - Thu Sep 19, 3:05PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The company expects this transition will be completed in the October-November time frame. Mr. Cross was previously Chief Financial Officer of Affymax (Nasdaq: AFFY), a publicly traded biopharmaceutical company. KaloBios previously announced Mr. Cooper's decision to retire in order to dedicate more time to family and personal interests.
Traders Get Bullish on Shares of Affymax, Shares Up 11.6% (AFFY)
Comtex SmarTrend(R) - Thu Aug 29, 11:44AM CDT
Affymax (NASDAQ:AFFY) is one of today's best performing low-priced stocks, up 11.6% to $1.75 on 1.5x average daily volume. Affymax has traded 1.9 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (11.5% to the Dow's 0.4%) and outperformed the S&P 500 (11.5% to the S&P's 0.5%) during today's trading.
GSAT, AFFY, AAMRQ and NVIV added to OTC Active Stock Watch List at EPR
ACCESSWIRE - Tue Aug 27, 7:57AM CDT
New York, NY - (ACCESSWIRE) - 08/27/2013 - Equity Profile Report initiates its OTC Active Stock Watch List adding Globalstar Inc. (OTC:GSAT), Affymax, Inc. (OTC:AFFY), AMR Corporation (OTC:AAMRQ) and InVivo Therapeutics Holdings Corp. (OTC:NVIV)
